 Adit Ginde
Concepts (554)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 82 | 2023 | 1813 | 9.210 |
Why?
| | Outpatients | 13 | 2023 | 328 | 4.050 |
Why?
| | Sepsis | 18 | 2023 | 508 | 4.040 |
Why?
| | Critical Illness | 18 | 2023 | 643 | 3.890 |
Why?
| | Vitamin D | 19 | 2021 | 341 | 3.230 |
Why?
| | Vitamin D Deficiency | 14 | 2021 | 158 | 2.990 |
Why?
| | Hospitalization | 40 | 2024 | 1754 | 2.780 |
Why?
| | Emergency Medicine | 13 | 2023 | 220 | 2.340 |
Why?
| | Cholecalciferol | 6 | 2021 | 47 | 2.340 |
Why?
| | Physician Assistants | 7 | 2014 | 66 | 2.310 |
Why?
| | Length of Stay | 20 | 2021 | 949 | 2.310 |
Why?
| | Hyperoxia | 4 | 2023 | 100 | 2.300 |
Why?
| | Patient Discharge | 11 | 2022 | 769 | 2.300 |
Why?
| | Adult | 133 | 2024 | 30608 | 2.250 |
Why?
| | Humans | 246 | 2024 | 114937 | 2.210 |
Why?
| | Hospital Mortality | 17 | 2023 | 776 | 2.170 |
Why?
| | Emergency Medical Services | 13 | 2023 | 587 | 2.130 |
Why?
| | United States | 85 | 2024 | 12211 | 2.040 |
Why?
| | Respiration, Artificial | 10 | 2023 | 526 | 2.000 |
Why?
| | Aged | 85 | 2023 | 19122 | 1.920 |
Why?
| | Ritonavir | 3 | 2023 | 71 | 1.830 |
Why?
| | Middle Aged | 105 | 2024 | 26806 | 1.810 |
Why?
| | Hospitals | 9 | 2023 | 581 | 1.800 |
Why?
| | Wounds and Injuries | 6 | 2022 | 723 | 1.780 |
Why?
| | Patient Transfer | 5 | 2015 | 144 | 1.740 |
Why?
| | Respiratory Tract Infections | 7 | 2021 | 321 | 1.710 |
Why?
| | Laryngoscopy | 7 | 2023 | 93 | 1.700 |
Why?
| | Health Services Accessibility | 11 | 2019 | 765 | 1.670 |
Why?
| | Male | 130 | 2023 | 55663 | 1.570 |
Why?
| | Influenza, Human | 10 | 2024 | 546 | 1.550 |
Why?
| | Oxygen | 8 | 2023 | 853 | 1.510 |
Why?
| | Patient Readmission | 5 | 2022 | 608 | 1.490 |
Why?
| | Cross-Sectional Studies | 34 | 2023 | 4407 | 1.460 |
Why?
| | Female | 127 | 2023 | 59581 | 1.420 |
Why?
| | Patient Admission | 7 | 2017 | 175 | 1.290 |
Why?
| | Retrospective Studies | 41 | 2023 | 12544 | 1.280 |
Why?
| | Nursing Homes | 3 | 2015 | 136 | 1.270 |
Why?
| | Laryngoscopes | 6 | 2023 | 38 | 1.250 |
Why?
| | Brain Injuries, Traumatic | 2 | 2023 | 300 | 1.240 |
Why?
| | Adolescent | 57 | 2024 | 17829 | 1.200 |
Why?
| | Rural Health Services | 8 | 2020 | 92 | 1.190 |
Why?
| | Influenza Vaccines | 9 | 2024 | 497 | 1.190 |
Why?
| | Aged, 80 and over | 28 | 2021 | 6364 | 1.190 |
Why?
| | Intensive Care Units | 5 | 2021 | 619 | 1.180 |
Why?
| | Vitamins | 7 | 2021 | 151 | 1.180 |
Why?
| | Physicians | 10 | 2023 | 772 | 1.160 |
Why?
| | Medicaid | 4 | 2015 | 407 | 1.110 |
Why?
| | Pneumonia | 5 | 2021 | 568 | 1.110 |
Why?
| | Health Care Surveys | 17 | 2020 | 539 | 1.090 |
Why?
| | Mass Screening | 7 | 2012 | 1011 | 1.090 |
Why?
| | Nurse Practitioners | 4 | 2012 | 102 | 1.060 |
Why?
| | Antibodies, Neutralizing | 6 | 2022 | 221 | 1.050 |
Why?
| | Referral and Consultation | 6 | 2022 | 634 | 1.030 |
Why?
| | Young Adult | 38 | 2024 | 10478 | 1.010 |
Why?
| | Stroke | 5 | 2022 | 1019 | 1.010 |
Why?
| | Rehabilitation Centers | 2 | 2015 | 32 | 1.000 |
Why?
| | Intubation, Intratracheal | 10 | 2023 | 215 | 0.980 |
Why?
| | Diabetes Mellitus | 6 | 2011 | 904 | 0.950 |
Why?
| | Insurance, Health | 5 | 2020 | 244 | 0.940 |
Why?
| | Shock, Traumatic | 1 | 2023 | 16 | 0.860 |
Why?
| | Medically Uninsured | 3 | 2014 | 122 | 0.860 |
Why?
| | Military Personnel | 4 | 2023 | 523 | 0.830 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2022 | 14 | 0.810 |
Why?
| | Minority Groups | 2 | 2023 | 228 | 0.810 |
Why?
| | Internship and Residency | 8 | 2023 | 944 | 0.810 |
Why?
| | Antiviral Agents | 6 | 2023 | 647 | 0.800 |
Why?
| | Health Services Needs and Demand | 3 | 2013 | 244 | 0.800 |
Why?
| | Airway Management | 1 | 2022 | 60 | 0.790 |
Why?
| | Primary Health Care | 6 | 2019 | 1515 | 0.780 |
Why?
| | Treatment Outcome | 24 | 2023 | 9105 | 0.780 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 52 | 0.780 |
Why?
| | Asthma | 11 | 2012 | 2042 | 0.780 |
Why?
| | Pneumonia, Viral | 6 | 2020 | 342 | 0.750 |
Why?
| | Coronavirus Infections | 6 | 2020 | 334 | 0.750 |
Why?
| | Patient Outcome Assessment | 2 | 2021 | 122 | 0.730 |
Why?
| | Critical Care | 5 | 2022 | 474 | 0.720 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 62 | 0.710 |
Why?
| | Career Choice | 3 | 2010 | 181 | 0.700 |
Why?
| | Pandemics | 11 | 2023 | 1325 | 0.700 |
Why?
| | Antibodies, Monoclonal | 6 | 2022 | 1270 | 0.690 |
Why?
| | Age Factors | 12 | 2019 | 2891 | 0.690 |
Why?
| | Tracheostomy | 1 | 2021 | 100 | 0.690 |
Why?
| | Personnel Selection | 2 | 2010 | 63 | 0.680 |
Why?
| | Resuscitation Orders | 2 | 2019 | 45 | 0.680 |
Why?
| | Spine | 1 | 2021 | 136 | 0.660 |
Why?
| | Translating | 2 | 2010 | 36 | 0.650 |
Why?
| | Warfare | 1 | 2019 | 74 | 0.640 |
Why?
| | Triage | 3 | 2020 | 192 | 0.640 |
Why?
| | Resuscitation | 1 | 2021 | 247 | 0.640 |
Why?
| | Conservative Treatment | 1 | 2018 | 29 | 0.620 |
Why?
| | Communication Barriers | 2 | 2010 | 89 | 0.610 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2019 | 129 | 0.610 |
Why?
| | Brain Ischemia | 3 | 2021 | 299 | 0.600 |
Why?
| | Prospective Studies | 17 | 2023 | 6218 | 0.600 |
Why?
| | Brain Injuries | 1 | 2023 | 452 | 0.600 |
Why?
| | Health Surveys | 4 | 2014 | 443 | 0.590 |
Why?
| | Obesity | 4 | 2022 | 2514 | 0.580 |
Why?
| | Guideline Adherence | 6 | 2022 | 490 | 0.580 |
Why?
| | Randomized Controlled Trials as Topic | 12 | 2023 | 1215 | 0.580 |
Why?
| | Sex Factors | 10 | 2019 | 1721 | 0.580 |
Why?
| | Databases, Factual | 10 | 2021 | 1125 | 0.560 |
Why?
| | Surgical Procedures, Operative | 2 | 2016 | 206 | 0.560 |
Why?
| | Language | 2 | 2010 | 258 | 0.550 |
Why?
| | Vaccination | 12 | 2024 | 1205 | 0.550 |
Why?
| | Professional Autonomy | 2 | 2014 | 25 | 0.550 |
Why?
| | MicroRNAs | 3 | 2017 | 601 | 0.550 |
Why?
| | Hydroxychloroquine | 3 | 2022 | 55 | 0.550 |
Why?
| | Interdisciplinary Studies | 1 | 2016 | 27 | 0.550 |
Why?
| | Financing, Organized | 1 | 2016 | 33 | 0.550 |
Why?
| | Orthopedics | 1 | 2018 | 121 | 0.540 |
Why?
| | Healthcare Disparities | 3 | 2012 | 480 | 0.540 |
Why?
| | Skilled Nursing Facilities | 2 | 2016 | 121 | 0.540 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 225 | 0.540 |
Why?
| | Communication | 2 | 2014 | 749 | 0.530 |
Why?
| | Home Care Services | 2 | 2016 | 222 | 0.530 |
Why?
| | Pilot Projects | 7 | 2023 | 1372 | 0.510 |
Why?
| | Acute Disease | 9 | 2020 | 915 | 0.510 |
Why?
| | Boston | 8 | 2010 | 75 | 0.510 |
Why?
| | Multiple Trauma | 1 | 2016 | 89 | 0.510 |
Why?
| | Severity of Illness Index | 11 | 2022 | 2542 | 0.500 |
Why?
| | Emergencies | 3 | 2015 | 146 | 0.500 |
Why?
| | Cross Infection | 2 | 2020 | 197 | 0.500 |
Why?
| | Catheterization, Central Venous | 1 | 2016 | 81 | 0.500 |
Why?
| | Hyperglycemia | 2 | 2009 | 292 | 0.500 |
Why?
| | Insurance Coverage | 3 | 2016 | 202 | 0.490 |
Why?
| | Antibodies, Viral | 4 | 2023 | 522 | 0.490 |
Why?
| | Homes for the Aged | 1 | 2015 | 19 | 0.490 |
Why?
| | Double-Blind Method | 12 | 2023 | 1663 | 0.480 |
Why?
| | Halfway Houses | 1 | 2014 | 2 | 0.480 |
Why?
| | Shock, Septic | 4 | 2018 | 185 | 0.470 |
Why?
| | Faculty, Medical | 1 | 2016 | 232 | 0.460 |
Why?
| | Nutrition Surveys | 6 | 2011 | 224 | 0.460 |
Why?
| | Patient Compliance | 3 | 2008 | 526 | 0.450 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 413 | 0.450 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2014 | 71 | 0.450 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 773 | 0.440 |
Why?
| | Risk Factors | 13 | 2021 | 8637 | 0.440 |
Why?
| | Dietary Supplements | 6 | 2021 | 458 | 0.440 |
Why?
| | Hypoglycemia | 2 | 2008 | 386 | 0.440 |
Why?
| | Point-of-Care Systems | 3 | 2011 | 139 | 0.440 |
Why?
| | Hospitals, Rural | 2 | 2010 | 31 | 0.440 |
Why?
| | Adenosine Monophosphate | 3 | 2021 | 49 | 0.440 |
Why?
| | Surveys and Questionnaires | 9 | 2017 | 4635 | 0.430 |
Why?
| | Urban Health Services | 5 | 2020 | 60 | 0.430 |
Why?
| | Betacoronavirus | 3 | 2020 | 253 | 0.430 |
Why?
| | Alanine | 3 | 2021 | 104 | 0.430 |
Why?
| | California | 5 | 2019 | 363 | 0.430 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 666 | 0.430 |
Why?
| | Medicare | 3 | 2015 | 666 | 0.420 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2017 | 287 | 0.420 |
Why?
| | Renal Dialysis | 1 | 2016 | 369 | 0.420 |
Why?
| | International Educational Exchange | 1 | 2012 | 11 | 0.420 |
Why?
| | International Classification of Diseases | 2 | 2014 | 117 | 0.410 |
Why?
| | Odds Ratio | 6 | 2018 | 954 | 0.410 |
Why?
| | Acute Kidney Injury | 3 | 2018 | 638 | 0.400 |
Why?
| | Health Resources | 1 | 2013 | 122 | 0.400 |
Why?
| | Oximetry | 2 | 2023 | 81 | 0.400 |
Why?
| | Treatment Failure | 6 | 2022 | 332 | 0.400 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 2326 | 0.400 |
Why?
| | Patient Education as Topic | 4 | 2010 | 678 | 0.400 |
Why?
| | Multivariate Analysis | 6 | 2016 | 1440 | 0.390 |
Why?
| | Time Factors | 14 | 2023 | 6125 | 0.390 |
Why?
| | Ambulatory Care | 5 | 2023 | 479 | 0.390 |
Why?
| | Hospital Units | 1 | 2011 | 23 | 0.390 |
Why?
| | Logistic Models | 7 | 2021 | 1844 | 0.380 |
Why?
| | Observation | 1 | 2011 | 50 | 0.380 |
Why?
| | Appointments and Schedules | 1 | 2011 | 73 | 0.380 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2024 | 139 | 0.380 |
Why?
| | Liability, Legal | 1 | 2011 | 38 | 0.380 |
Why?
| | Hyperparathyroidism, Secondary | 1 | 2011 | 9 | 0.380 |
Why?
| | Patient Safety | 2 | 2016 | 278 | 0.380 |
Why?
| | Inflammation Mediators | 1 | 2014 | 476 | 0.380 |
Why?
| | Inpatients | 2 | 2021 | 380 | 0.380 |
Why?
| | Malpractice | 1 | 2011 | 37 | 0.380 |
Why?
| | Colorado | 8 | 2023 | 4091 | 0.380 |
Why?
| | Blood Glucose | 3 | 2008 | 1821 | 0.370 |
Why?
| | Training Support | 1 | 2010 | 22 | 0.370 |
Why?
| | Cohort Studies | 13 | 2023 | 4903 | 0.360 |
Why?
| | Multicenter Studies as Topic | 5 | 2023 | 250 | 0.360 |
Why?
| | Health Care Rationing | 1 | 2010 | 45 | 0.360 |
Why?
| | Parathyroid Hormone | 1 | 2011 | 95 | 0.360 |
Why?
| | Personnel, Hospital | 2 | 2020 | 24 | 0.360 |
Why?
| | Inflammation | 1 | 2021 | 2485 | 0.350 |
Why?
| | Military Medicine | 2 | 2022 | 93 | 0.350 |
Why?
| | Digital Rectal Examination | 1 | 2010 | 10 | 0.350 |
Why?
| | Electronic Health Records | 3 | 2023 | 802 | 0.350 |
Why?
| | Occult Blood | 1 | 2010 | 26 | 0.350 |
Why?
| | Risk Assessment | 8 | 2021 | 2975 | 0.340 |
Why?
| | Child | 21 | 2022 | 18366 | 0.340 |
Why?
| | Patient Care | 1 | 2010 | 103 | 0.340 |
Why?
| | Ambulances | 3 | 2023 | 50 | 0.340 |
Why?
| | Intrauterine Devices | 1 | 2009 | 24 | 0.330 |
Why?
| | Body Mass Index | 4 | 2019 | 1961 | 0.320 |
Why?
| | Cause of Death | 2 | 2017 | 363 | 0.320 |
Why?
| | Influenza A Virus, H3N2 Subtype | 3 | 2024 | 40 | 0.320 |
Why?
| | Socioeconomic Factors | 5 | 2015 | 1081 | 0.320 |
Why?
| | South Africa | 3 | 2023 | 161 | 0.310 |
Why?
| | Atracurium | 2 | 2019 | 13 | 0.310 |
Why?
| | Neuromuscular Blocking Agents | 2 | 2019 | 24 | 0.300 |
Why?
| | Mathematics | 1 | 2008 | 101 | 0.300 |
Why?
| | Disease Models, Animal | 1 | 2017 | 3549 | 0.300 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2015 | 1183 | 0.290 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3053 | 0.290 |
Why?
| | Age Distribution | 4 | 2014 | 340 | 0.280 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2009 | 928 | 0.280 |
Why?
| | Decision Support Systems, Clinical | 2 | 2021 | 177 | 0.280 |
Why?
| | Acute Lung Injury | 2 | 2022 | 300 | 0.270 |
Why?
| | Prevalence | 6 | 2014 | 2252 | 0.270 |
Why?
| | Ivermectin | 2 | 2023 | 10 | 0.270 |
Why?
| | Cognitive Dysfunction | 2 | 2021 | 273 | 0.270 |
Why?
| | Community-Acquired Infections | 2 | 2020 | 141 | 0.260 |
Why?
| | Data Collection | 4 | 2014 | 623 | 0.260 |
Why?
| | Case-Control Studies | 9 | 2022 | 3008 | 0.250 |
Why?
| | Emergency Treatment | 3 | 2019 | 113 | 0.250 |
Why?
| | Pregnancy Complications | 1 | 2010 | 430 | 0.250 |
Why?
| | Staphylococcal Infections | 1 | 2009 | 336 | 0.250 |
Why?
| | Child, Preschool | 12 | 2019 | 9086 | 0.240 |
Why?
| | Hospitals, Urban | 3 | 2016 | 127 | 0.240 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 125 | 0.240 |
Why?
| | Disease Progression | 5 | 2021 | 2392 | 0.240 |
Why?
| | Physician-Patient Relations | 1 | 2009 | 463 | 0.230 |
Why?
| | Fluid Therapy | 2 | 2023 | 122 | 0.230 |
Why?
| | Choice Behavior | 2 | 2019 | 155 | 0.230 |
Why?
| | Calcitriol | 2 | 2014 | 53 | 0.230 |
Why?
| | Diabetic Ketoacidosis | 1 | 2006 | 160 | 0.230 |
Why?
| | Medical Audit | 2 | 2018 | 75 | 0.230 |
Why?
| | Chronic Disease | 3 | 2022 | 1593 | 0.230 |
Why?
| | Ambulatory Care Facilities | 3 | 2020 | 213 | 0.230 |
Why?
| | Patient Acceptance of Health Care | 2 | 2020 | 679 | 0.230 |
Why?
| | Seasons | 5 | 2024 | 449 | 0.230 |
Why?
| | Organ Dysfunction Scores | 2 | 2020 | 39 | 0.220 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 978 | 0.220 |
Why?
| | Influenza A virus | 1 | 2024 | 90 | 0.220 |
Why?
| | Hypotension | 2 | 2023 | 113 | 0.220 |
Why?
| | RNA, Messenger | 7 | 2023 | 2559 | 0.220 |
Why?
| | Comorbidity | 4 | 2021 | 1458 | 0.220 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2023 | 20 | 0.220 |
Why?
| | Androstadienes | 1 | 2023 | 97 | 0.220 |
Why?
| | Electronics | 1 | 2023 | 66 | 0.210 |
Why?
| | Immunocompromised Host | 2 | 2022 | 196 | 0.210 |
Why?
| | Urinary Tract Infections | 1 | 2004 | 133 | 0.210 |
Why?
| | Lopinavir | 1 | 2022 | 29 | 0.210 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2023 | 61 | 0.210 |
Why?
| | Renin-Angiotensin System | 1 | 2023 | 71 | 0.210 |
Why?
| | Recovery of Function | 3 | 2022 | 572 | 0.210 |
Why?
| | Delirium | 1 | 2023 | 66 | 0.210 |
Why?
| | Cytokines | 2 | 2014 | 1843 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 98 | 0.200 |
Why?
| | Health Services Research | 2 | 2016 | 371 | 0.200 |
Why?
| | Syncope | 1 | 2022 | 37 | 0.200 |
Why?
| | Biomarkers | 7 | 2021 | 3418 | 0.200 |
Why?
| | Vasoconstrictor Agents | 2 | 2023 | 112 | 0.200 |
Why?
| | Incidence | 3 | 2019 | 2316 | 0.200 |
Why?
| | Immunization, Secondary | 1 | 2022 | 82 | 0.190 |
Why?
| | Veterans Health | 1 | 2023 | 165 | 0.190 |
Why?
| | Rural Population | 3 | 2016 | 447 | 0.190 |
Why?
| | Positive-Pressure Respiration | 2 | 2019 | 68 | 0.190 |
Why?
| | Polypharmacy | 1 | 2022 | 74 | 0.190 |
Why?
| | Hypoxia | 3 | 2023 | 960 | 0.190 |
Why?
| | Academic Medical Centers | 4 | 2020 | 415 | 0.190 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 10 | 0.190 |
Why?
| | Malawi | 1 | 2021 | 48 | 0.190 |
Why?
| | Drug Prescriptions | 1 | 2003 | 239 | 0.190 |
Why?
| | Immunization Programs | 1 | 2023 | 206 | 0.190 |
Why?
| | Wounds, Penetrating | 1 | 2022 | 69 | 0.190 |
Why?
| | Abdominal Pain | 1 | 2022 | 136 | 0.190 |
Why?
| | Vasodilator Agents | 1 | 2023 | 305 | 0.190 |
Why?
| | Quality of Health Care | 3 | 2010 | 573 | 0.190 |
Why?
| | Bayes Theorem | 1 | 2022 | 331 | 0.190 |
Why?
| | Work | 1 | 2020 | 17 | 0.180 |
Why?
| | Infant | 7 | 2019 | 7937 | 0.180 |
Why?
| | Aftercare | 1 | 2022 | 187 | 0.180 |
Why?
| | Telecommunications | 1 | 2020 | 16 | 0.180 |
Why?
| | Contact Tracing | 1 | 2020 | 16 | 0.180 |
Why?
| | Neuromuscular Blockade | 2 | 2019 | 22 | 0.180 |
Why?
| | Personnel Turnover | 2 | 2010 | 27 | 0.180 |
Why?
| | Video Recording | 4 | 2023 | 142 | 0.180 |
Why?
| | Adrenergic beta-Agonists | 2 | 2012 | 126 | 0.180 |
Why?
| | Electrocardiography | 1 | 2003 | 562 | 0.180 |
Why?
| | Organ Transplantation | 1 | 2022 | 159 | 0.170 |
Why?
| | Physical Therapy Modalities | 1 | 2023 | 264 | 0.170 |
Why?
| | Chi-Square Distribution | 3 | 2012 | 495 | 0.170 |
Why?
| | Abbreviated Injury Scale | 1 | 2019 | 21 | 0.170 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2020 | 79 | 0.170 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 291 | 0.170 |
Why?
| | Symptom Assessment | 1 | 2020 | 118 | 0.170 |
Why?
| | Continuity of Patient Care | 2 | 2012 | 254 | 0.170 |
Why?
| | Iraq | 1 | 2019 | 81 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 5 | 2021 | 499 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 1856 | 0.160 |
Why?
| | Agkistrodon | 1 | 2019 | 19 | 0.160 |
Why?
| | Crotalid Venoms | 1 | 2019 | 31 | 0.160 |
Why?
| | Afghanistan | 1 | 2019 | 108 | 0.160 |
Why?
| | Dantrolene | 1 | 2019 | 5 | 0.160 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2019 | 69 | 0.160 |
Why?
| | Neuromuscular Depolarizing Agents | 1 | 2019 | 5 | 0.160 |
Why?
| | Malignant Hyperthermia | 1 | 2019 | 7 | 0.160 |
Why?
| | Muscle Relaxants, Central | 1 | 2019 | 9 | 0.160 |
Why?
| | Succinylcholine | 1 | 2019 | 7 | 0.160 |
Why?
| | Lactic Acid | 1 | 2020 | 275 | 0.160 |
Why?
| | Antivenins | 1 | 2019 | 56 | 0.160 |
Why?
| | Needs Assessment | 3 | 2010 | 315 | 0.160 |
Why?
| | Consensus | 1 | 2021 | 534 | 0.160 |
Why?
| | Quality Indicators, Health Care | 2 | 2012 | 287 | 0.160 |
Why?
| | Iraq War, 2003-2011 | 1 | 2019 | 151 | 0.160 |
Why?
| | Injury Severity Score | 2 | 2022 | 457 | 0.160 |
Why?
| | Snake Bites | 1 | 2019 | 54 | 0.160 |
Why?
| | Afghan Campaign 2001- | 1 | 2019 | 162 | 0.160 |
Why?
| | Platelet-Rich Plasma | 1 | 2018 | 23 | 0.160 |
Why?
| | Formative Feedback | 1 | 2018 | 23 | 0.150 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2019 | 78 | 0.150 |
Why?
| | Time-to-Treatment | 4 | 2021 | 147 | 0.150 |
Why?
| | Survivors | 1 | 2021 | 411 | 0.150 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 1729 | 0.150 |
Why?
| | Vaccines | 1 | 2023 | 376 | 0.150 |
Why?
| | Clinical Competence | 2 | 2010 | 901 | 0.150 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 94 | 0.150 |
Why?
| | Hospitals, Teaching | 2 | 2011 | 102 | 0.150 |
Why?
| | Cognition | 2 | 2023 | 983 | 0.150 |
Why?
| | Specimen Handling | 1 | 2018 | 156 | 0.140 |
Why?
| | Maryland | 1 | 2017 | 37 | 0.140 |
Why?
| | Certification | 3 | 2020 | 89 | 0.140 |
Why?
| | Income | 2 | 2008 | 167 | 0.140 |
Why?
| | Civil Defense | 1 | 2017 | 18 | 0.140 |
Why?
| | Oxygen Consumption | 1 | 2019 | 588 | 0.140 |
Why?
| | Environmental Exposure | 1 | 2020 | 377 | 0.140 |
Why?
| | Assisted Living Facilities | 1 | 2016 | 9 | 0.140 |
Why?
| | Accidental Falls | 2 | 2016 | 150 | 0.140 |
Why?
| | Fibroblast Growth Factors | 1 | 2018 | 162 | 0.140 |
Why?
| | Executive Function | 1 | 2021 | 376 | 0.140 |
Why?
| | Trachea | 3 | 2023 | 235 | 0.140 |
Why?
| | Avalanches | 1 | 2016 | 3 | 0.130 |
Why?
| | Educational Status | 2 | 2008 | 409 | 0.130 |
Why?
| | Orthopedic Procedures | 1 | 2018 | 208 | 0.130 |
Why?
| | Registries | 2 | 2022 | 1760 | 0.130 |
Why?
| | Mountaineering | 1 | 2016 | 47 | 0.130 |
Why?
| | Anesthesiology | 1 | 2016 | 35 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1801 | 0.130 |
Why?
| | Colitis, Ulcerative | 1 | 2017 | 105 | 0.130 |
Why?
| | Advance Directives | 1 | 2016 | 69 | 0.130 |
Why?
| | Urban Population | 3 | 2010 | 402 | 0.130 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 756 | 0.130 |
Why?
| | AIDS Serodiagnosis | 2 | 2012 | 29 | 0.120 |
Why?
| | Infant, Newborn | 3 | 2014 | 5035 | 0.120 |
Why?
| | Efficiency, Organizational | 1 | 2016 | 126 | 0.120 |
Why?
| | Precision Medicine | 1 | 2018 | 339 | 0.120 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 183 | 0.120 |
Why?
| | Awareness | 1 | 2015 | 92 | 0.120 |
Why?
| | Evidence-Based Medicine | 2 | 2016 | 675 | 0.120 |
Why?
| | Perioperative Care | 1 | 2016 | 126 | 0.120 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 191 | 0.120 |
Why?
| | Neoplasms | 1 | 2008 | 2106 | 0.120 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 546 | 0.120 |
Why?
| | Frail Elderly | 1 | 2015 | 105 | 0.110 |
Why?
| | Creatinine | 1 | 2015 | 424 | 0.110 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2014 | 24 | 0.110 |
Why?
| | Quality Improvement | 1 | 2021 | 954 | 0.110 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 817 | 0.110 |
Why?
| | Health Care Costs | 1 | 2017 | 380 | 0.110 |
Why?
| | Crohn Disease | 1 | 2017 | 196 | 0.110 |
Why?
| | Confidence Intervals | 3 | 2010 | 309 | 0.110 |
Why?
| | Fluvoxamine | 2 | 2023 | 12 | 0.110 |
Why?
| | Patient-Centered Care | 2 | 2016 | 473 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2020 | 834 | 0.110 |
Why?
| | Risk | 2 | 2017 | 815 | 0.110 |
Why?
| | Pneumonia, Bacterial | 1 | 2014 | 106 | 0.110 |
Why?
| | Influenza B virus | 2 | 2024 | 34 | 0.110 |
Why?
| | Vaccines, Combined | 2 | 2022 | 46 | 0.110 |
Why?
| | Physician's Role | 1 | 2014 | 198 | 0.100 |
Why?
| | Headache | 1 | 2013 | 132 | 0.100 |
Why?
| | Preventive Health Services | 2 | 2012 | 135 | 0.100 |
Why?
| | Anti-Bacterial Agents | 4 | 2018 | 1477 | 0.100 |
Why?
| | Hospital Costs | 1 | 2013 | 103 | 0.100 |
Why?
| | Adaptive Clinical Trials as Topic | 2 | 2022 | 19 | 0.100 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1126 | 0.100 |
Why?
| | Neutrophils | 1 | 2017 | 1164 | 0.100 |
Why?
| | Immune System | 1 | 2013 | 173 | 0.100 |
Why?
| | Sampling Studies | 1 | 2012 | 93 | 0.100 |
Why?
| | Oregon | 1 | 2011 | 66 | 0.100 |
Why?
| | Georgia | 1 | 2011 | 62 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2017 | 958 | 0.100 |
Why?
| | Sex Distribution | 2 | 2013 | 336 | 0.100 |
Why?
| | Fractures, Bone | 1 | 2016 | 367 | 0.100 |
Why?
| | Massachusetts | 1 | 2011 | 134 | 0.100 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 4719 | 0.090 |
Why?
| | HIV | 1 | 2012 | 208 | 0.090 |
Why?
| | Drug Administration Schedule | 3 | 2019 | 718 | 0.090 |
Why?
| | Mice, Knockout | 1 | 2017 | 2587 | 0.090 |
Why?
| | Specialization | 1 | 2011 | 115 | 0.090 |
Why?
| | Viral Load | 2 | 2023 | 405 | 0.090 |
Why?
| | Professional Practice Location | 1 | 2010 | 26 | 0.090 |
Why?
| | Statistics, Nonparametric | 2 | 2009 | 387 | 0.090 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2011 | 99 | 0.090 |
Why?
| | Health Care Reform | 1 | 2011 | 92 | 0.090 |
Why?
| | Bias | 2 | 2021 | 180 | 0.090 |
Why?
| | Workload | 1 | 2011 | 132 | 0.090 |
Why?
| | Legislation as Topic | 1 | 2010 | 4 | 0.090 |
Why?
| | Delegation, Professional | 1 | 2010 | 1 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1177 | 0.090 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 75 | 0.090 |
Why?
| | Medically Underserved Area | 1 | 2010 | 81 | 0.090 |
Why?
| | Social Class | 2 | 2009 | 204 | 0.090 |
Why?
| | Occupations | 1 | 2010 | 36 | 0.090 |
Why?
| | Emergency Nursing | 1 | 2010 | 19 | 0.090 |
Why?
| | Quality of Life | 1 | 2021 | 2359 | 0.090 |
Why?
| | Altitude | 1 | 2014 | 433 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1700 | 0.090 |
Why?
| | Mental Health Services | 1 | 2014 | 317 | 0.090 |
Why?
| | Motivation | 2 | 2012 | 495 | 0.090 |
Why?
| | Allied Health Personnel | 1 | 2010 | 42 | 0.090 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 372 | 0.090 |
Why?
| | Albuterol | 1 | 2010 | 103 | 0.090 |
Why?
| | Algorithms | 1 | 2017 | 1474 | 0.080 |
Why?
| | Geriatric Assessment | 1 | 2011 | 176 | 0.080 |
Why?
| | Medical Order Entry Systems | 1 | 2010 | 41 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2011 | 251 | 0.080 |
Why?
| | Population | 1 | 2009 | 28 | 0.080 |
Why?
| | RNA, Viral | 2 | 2023 | 566 | 0.080 |
Why?
| | Specialty Boards | 1 | 2009 | 34 | 0.080 |
Why?
| | Job Satisfaction | 1 | 2010 | 168 | 0.080 |
Why?
| | Insulin | 2 | 2009 | 2079 | 0.080 |
Why?
| | Nutritional Status | 1 | 2011 | 286 | 0.080 |
Why?
| | Schools, Veterinary | 1 | 2008 | 2 | 0.080 |
Why?
| | Self Report | 2 | 2023 | 696 | 0.080 |
Why?
| | Forced Expiratory Volume | 1 | 2010 | 476 | 0.080 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2008 | 46 | 0.080 |
Why?
| | Nurses | 1 | 2010 | 144 | 0.080 |
Why?
| | Disease Management | 2 | 2011 | 563 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2009 | 285 | 0.080 |
Why?
| | Professional Role | 1 | 2010 | 152 | 0.080 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 954 | 0.080 |
Why?
| | Smoking Cessation | 1 | 2012 | 374 | 0.080 |
Why?
| | Interleukin-10 | 1 | 2010 | 296 | 0.080 |
Why?
| | Device Removal | 1 | 2009 | 127 | 0.080 |
Why?
| | Mexican Americans | 1 | 2009 | 102 | 0.080 |
Why?
| | Animals | 4 | 2019 | 31839 | 0.080 |
Why?
| | Glucocorticoids | 2 | 2023 | 534 | 0.070 |
Why?
| | Mental Recall | 2 | 2021 | 170 | 0.070 |
Why?
| | Immunity, Innate | 2 | 2014 | 725 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2008 | 294 | 0.070 |
Why?
| | Feasibility Studies | 2 | 2023 | 737 | 0.070 |
Why?
| | Health Status Indicators | 1 | 2008 | 154 | 0.070 |
Why?
| | Morbidity | 1 | 2008 | 277 | 0.070 |
Why?
| | Glucose Tolerance Test | 1 | 2008 | 343 | 0.070 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 934 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 323 | 0.070 |
Why?
| | Liver Transplantation | 1 | 2014 | 706 | 0.070 |
Why?
| | Forecasting | 1 | 2008 | 333 | 0.070 |
Why?
| | RNA | 2 | 2023 | 810 | 0.070 |
Why?
| | Administration, Inhalation | 2 | 2023 | 642 | 0.070 |
Why?
| | Qualitative Research | 2 | 2022 | 936 | 0.070 |
Why?
| | Virus Diseases | 1 | 2008 | 196 | 0.070 |
Why?
| | Papillomavirus Vaccines | 1 | 2009 | 223 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1080 | 0.070 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 343 | 0.070 |
Why?
| | Papillomavirus Infections | 1 | 2009 | 262 | 0.070 |
Why?
| | Geography | 1 | 2006 | 181 | 0.060 |
Why?
| | History, 21st Century | 1 | 2006 | 161 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 385 | 0.060 |
Why?
| | Self Care | 1 | 2008 | 350 | 0.060 |
Why?
| | History, 20th Century | 1 | 2006 | 267 | 0.060 |
Why?
| | Calcium | 1 | 2011 | 1104 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1227 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2015 | 2133 | 0.060 |
Why?
| | Lung | 1 | 2017 | 3593 | 0.060 |
Why?
| | Prognosis | 2 | 2020 | 3344 | 0.060 |
Why?
| | Missouri | 1 | 2004 | 62 | 0.060 |
Why?
| | Sex Characteristics | 1 | 2008 | 635 | 0.060 |
Why?
| | Patient Acuity | 1 | 2023 | 42 | 0.060 |
Why?
| | Angiotensins | 1 | 2023 | 10 | 0.050 |
Why?
| | Macrolides | 1 | 2003 | 56 | 0.050 |
Why?
| | Calibration | 1 | 2023 | 125 | 0.050 |
Why?
| | Remission Induction | 1 | 2023 | 233 | 0.050 |
Why?
| | Drug Repositioning | 1 | 2022 | 13 | 0.050 |
Why?
| | Angiotensin II | 1 | 2023 | 90 | 0.050 |
Why?
| | Nucleocapsid | 1 | 2022 | 17 | 0.050 |
Why?
| | Emergency Medical Dispatch | 1 | 2022 | 6 | 0.050 |
Why?
| | Immunocompetence | 1 | 2022 | 40 | 0.050 |
Why?
| | Medical Futility | 1 | 2021 | 19 | 0.050 |
Why?
| | Syndrome | 1 | 2022 | 336 | 0.050 |
Why?
| | Information Systems | 1 | 2022 | 61 | 0.050 |
Why?
| | Health Promotion | 2 | 2022 | 686 | 0.050 |
Why?
| | Pulse Therapy, Drug | 1 | 2021 | 6 | 0.050 |
Why?
| | Oligopeptides | 1 | 2023 | 235 | 0.050 |
Why?
| | HIV Infections | 2 | 2012 | 2470 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 565 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2021 | 73 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2021 | 176 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2022 | 140 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 68 | 0.050 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2008 | 1008 | 0.050 |
Why?
| | Personnel Staffing and Scheduling | 2 | 2011 | 79 | 0.050 |
Why?
| | Immunization | 1 | 2023 | 402 | 0.050 |
Why?
| | Antimalarials | 1 | 2020 | 24 | 0.050 |
Why?
| | Immunization Schedule | 1 | 2022 | 184 | 0.040 |
Why?
| | Documentation | 1 | 2022 | 169 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2009 | 4427 | 0.040 |
Why?
| | Vaccination Coverage | 1 | 2021 | 63 | 0.040 |
Why?
| | Health Facilities | 1 | 2021 | 72 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2020 | 138 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 50 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 75 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2020 | 258 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2022 | 617 | 0.040 |
Why?
| | Practice Guidelines as Topic | 2 | 2022 | 1400 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2003 | 374 | 0.040 |
Why?
| | ROC Curve | 1 | 2020 | 448 | 0.040 |
Why?
| | Ergocalciferols | 1 | 2019 | 11 | 0.040 |
Why?
| | Program Evaluation | 1 | 2003 | 824 | 0.040 |
Why?
| | Conscious Sedation | 1 | 2019 | 79 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 296 | 0.040 |
Why?
| | Pregnancy | 1 | 2010 | 5527 | 0.040 |
Why?
| | Renal Replacement Therapy | 1 | 2018 | 66 | 0.040 |
Why?
| | RNA Transport | 1 | 2017 | 23 | 0.040 |
Why?
| | Workflow | 1 | 2018 | 135 | 0.040 |
Why?
| | Informed Consent | 1 | 2018 | 161 | 0.040 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 13 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 817 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.040 |
Why?
| | Africa | 1 | 2017 | 95 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2021 | 913 | 0.030 |
Why?
| | Historically Controlled Study | 1 | 2016 | 5 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 299 | 0.030 |
Why?
| | Ghana | 1 | 2015 | 30 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 280 | 0.030 |
Why?
| | Depression | 1 | 2023 | 1134 | 0.030 |
Why?
| | Reimbursement, Incentive | 1 | 2015 | 35 | 0.030 |
Why?
| | Mortality | 1 | 2017 | 288 | 0.030 |
Why?
| | Cathelicidins | 1 | 2014 | 38 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2014 | 201 | 0.030 |
Why?
| | Muscle Strength | 1 | 2017 | 270 | 0.030 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2014 | 75 | 0.030 |
Why?
| | Nanoparticles | 1 | 2017 | 313 | 0.030 |
Why?
| | Clinical Coding | 1 | 2013 | 19 | 0.030 |
Why?
| | Internet | 1 | 2017 | 599 | 0.030 |
Why?
| | Research Design | 1 | 2018 | 932 | 0.030 |
Why?
| | Bed Occupancy | 1 | 2011 | 10 | 0.020 |
Why?
| | Domestic Violence | 1 | 2011 | 41 | 0.020 |
Why?
| | Resource Allocation | 1 | 2010 | 37 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2382 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 41 | 0.020 |
Why?
| | Pamphlets | 1 | 2010 | 24 | 0.020 |
Why?
| | Demography | 1 | 2010 | 262 | 0.020 |
Why?
| | Tobacco Use Disorder | 1 | 2012 | 234 | 0.020 |
Why?
| | Consumer Health Information | 1 | 2010 | 47 | 0.020 |
Why?
| | Self Efficacy | 1 | 2012 | 355 | 0.020 |
Why?
| | Psychometrics | 1 | 2012 | 608 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2012 | 583 | 0.020 |
Why?
| | Teaching | 1 | 2010 | 223 | 0.020 |
Why?
| | Research | 1 | 2011 | 395 | 0.020 |
Why?
| | Linear Models | 1 | 2009 | 770 | 0.020 |
Why?
| | Anti-Asthmatic Agents | 1 | 2010 | 350 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2012 | 2770 | 0.020 |
Why?
|
|
Ginde's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|